Conference abstract · 7 Nov 2016
Conference abstractPublished 8 Sep 2014
Why aren’t biosimilars generics - regulatory challenges
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Biological products, derived from mammalian, bacterial, or from animal origins constitute many of today?s important medications. As numerous patents protecting originator biological products are expiring, the development of ?Generic Biologics? products aka biosimilars become a lucrative and exciting opportunity for many ?traditional generic? and international pharmaceutical companies. Unlike small molecule drugs, generally targeted by the ?traditional generic? industry, biological products are usually highly complex in structure. This presentation will highlight the differences between the regulation covering generic ?small molecule? drugs and biosimilar-based drugs and focus on the regulatory challenges in implementing the new regulations.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 23 Jun 2023
From biosimilars to affordable copies of biologics; access opportunities, scientific and regulatory challenges and emerging solutions
Article · 17 Jun 2024
Generic and Biosimilar Drug Interchangeability and Innovations
Commentary · 27 Oct 2021
Critical Differences in Generics and Biosimilars
Article · 12 Jun 2026
Regulatory Requirements in Bioequivalence Studies for Generic Drug Approval
More from this journal
The newest in Pharmaceutical Regulatory Affairs: Open Access.
Article · 13 Feb 2026
Regulatory Scenario of Pharmaceuticals during COVID-19 Pandemic in India
Article · 11 Feb 2026
EU GMP Annex 1 of 2022: A View in Depth
Article · 11 Feb 2026
Standard Formats Used in Drug Regulatory Submissions and Software Used
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutical Regulatory Affairs: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Adam Sabouni”

